Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $(0.30) by 290 percent. This is a 207.55 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $84.93 million which beat the analyst consensus estimate of $14.25 million by 495.99 percent. This is a 7.88K percent increase over sales of $1.06 million the same period last year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。